Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Clin Cancer Res. 2016 May 25;22(19):4776–4785. doi: 10.1158/1078-0432.CCR-16-0506

Figure 4. Overall survival from date of surgery for different patient sub-sets.

Figure 4

A) Median OS was 15.3 months for all patients (n = 44), 14.4 months for patients in Cohort 1 (n =22) and 15.7 months for patients in Cohort 2 (n = 22). There was no significant difference between each of the cohorts (p = 0.63, Log-rank test); one patient was lost for follow up in Cohort 2 and excluded from survival analysis. B) Relationship between survival and TUMAP response. Only patients that were immune evaluable were included in the analysis. Log-rank test was used to calculate significance between the two different patient populations. C) Relationship between overall survival and injection site reaction. One patient was lost to survival follow up and is excluded from the analysis. Log-rank test was used to calculate significance and hazard ratio. Median age of patients in the ISR group was significantly lower than that of the non-ISR (47 versus 57 years respectively; p = 0.023 by Mann Whitney test).

Abbreviations: HR, hazard ratio; ISR, injection site reaction; TUMAP, tumor associated peptide; y, years.